Risk factors for recurrent breast cancer after combination treatment



Cite item

Full Text

Abstract

Two hundred and eighteen patients aged 31 to 92 years (mean age 57+1.3 years), who had been treated for breast cancer (BC), were examined. They were divided into 2 groups: 1) 99 patients who had undergone organ-sparing surgery (OSS) and 2) 119 patients after radical mastectomy (RME). The degree of primary tumor differentiation, metastases to regional lymph nodes, and the immunohistochemical pattern of a tumor (ER, PR, and HER-2/neu) were assessed as prognostic factors. The local recurrence rate was found to be 13 and 9% in Groups 1 and 2, respectively. The relapse-free period averaged 53+8 and 56+10 months in Groups 1 and 2, respectively. The degree of tumor differentiation, metastases to regional lymph nodes, the receptor status (ER, PR) of a primary tumor in both groups, and the expression of HER-2/neu after RME do not affect the occurrence of recurrent BC at the 0.05 significance level. In the post-OSS patients, the HER-2/neu-positive primary tumor showed a statistically significant correlation with the rate of recurrent BC at the 0.05 significance level.

References

  1. Лапач С. Н., Чубенко А. В., Бабич П. Н. // Статистика в науке и бизнесе. - Киев, 2002. - Р. 195-207.
  2. Blichert-Toft M., Rose С., Andersen J. A. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 19-25.
  3. Botteri E., Bagnardi V., Rotmensz N. et al. // Ann. Oncol. - 2009. - Vol. 10. - P. 386.
  4. Fisher B., Bauer M., Margolese R. et al. // N. Engl. J. Med. - 1985. - Vol. 312. - P. 665-673.
  5. Fitzgibbons M. D. et al. // Arch. Pathol. Lab. Med. - 2000. - Vol. 124. - P. 966-978.
  6. Freedman G. et al. // Oncology. - 2000. - Vol. 14, N 11. - P. 1561-1581.
  7. Maddox W. A., Carpenter J. T. Jr., Laws H. L. et al. // Ann. Surg. - 1983. - Vol. 198. - P. 207-212.
  8. Pisani Р., Parkin D. M., Bray F., Ferlay J. // Int. J. Cancer. - 1999. - Vol. 83. - P. 870-873.
  9. Pisani P., Forman D. // Br. J. Cancer. - 2004. - Vol. 90. - P. 652-656.
  10. Sarrazin D., Lé M, Rouésse J. et al. // Cancer. - 1984. - Vol. 53. - P. 1209-1213.
  11. Straus K., Lichter A., Lippman M. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 27-32.
  12. van Dongen J. A., Bartelink H., Fentiman I. S. et al. // Monogr. Natl. Cancer Inst. - 1992. - Vol. 11. - P. 15-18.
  13. Veronesi U., Saccozzi R., Del Vecchio M. et al. // N. Engl. J. Med. - 1981. - Vol. 305. - P. 6-11.
  14. Voogd A. C., Nielsen M., Peterse J. L. et al. // J. Clin. Oncol. - 2001. - Vol. 19, N 6. - P. 1688-1697.
  15. World Health Organisation. Steward B. W., Kleihues P., eds. // World Cancer Report. - Lyon, 2003.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Eco-Vector


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ПИ № ФС 77 - 86496 от 11.12.2023 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: ЭЛ № ФС 77 - 80673 от 23.03.2021 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies